Application noteSee All
Avacta's unique technology enables Affimer® affinity resins to be developed to a range of molecules for affinity purification purposes.
We have developed Affimers to a recombinant form of the Zika virus NS1 protein that is diagnostic of Zika infection at the early, acute phase. In just 16 weeks we generated specific Affimer binders to this challenging target, and have demonstrated their effectiveness in ELISA/immunoassay format for specific detection of the Zika NS1 antigen at clinically relevant concentrations.
White paperSee All
New white paper examines a range of alternatives to antibodies This paper reviews the main applications of affnity binders and the requirements placed on them according to application.
Feature article by our CSO Paul Ko Ferrigno published in Drug Discovery Today.
Preliminary AnnouncementSee All
Please note: This file is an audio / video webcast and requires the WebEx ARF player to playback the recording. Download ARF player here.
Preliminary Results for the Year Ended 31 July 2015.
This case study outlines Affimer technology for the generation of cancer immune checkpoint inhibitors, to demonstrate the rapid identification of a number of biotherapeutic candidate molecules.
A case study looking at the findings of a published study on the HIF-1α/p300 protein–protein interaction, which plays a key role in tumor metabolism and thus represents a high value target for anticancer drug-development.
One of the key advantages of Affimer technology over the more established affinity reagents is the ability to tailor specificity and affinity to suit your needs. Find out more details in our case study.
Annual ReportSee All
General MeetingsSee All
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier
Notice of the annual general meeting of the Company to be held at the officces of FTI Consulting at 200 Aldersgate, Aldersgate Street, London EC1A 4HD on Friday 20 January 2017 at 10.00 a.m.
Interim AnnouncementsSee All
Interim Results Analyst Presentation 2016
Affimer biotherapeutics are a new protein scaffold with great potential for the generation of biotherapeutics. Based on the human protease inhibitor Stefin A, the scaffold is small (12kDa), lacks any post translational modifications such as disulphide bonds and glycosylation.
This poster reports the identification and initial characterisation of highly specific binders to the Zika NS1 protein.
Purification of tag-free proteins, a vital step for many research and industrial applications, is commonly facilitated by affinity chromatography where the target protein is captured from a complex mixture by an affinity resin and then eluted in an appropriate buffer.
Investor infoSee All
Published PaperSee All
An ultraefficient cap-exchange protocol (UCEP) that can convert hydrophobic quantum dots (QDs) into stable, biocompatible, and aggregation-free water-dispersed ones at a ligand:QD molar ratio (LQMR) as low as 500, some 20−200-fold less than most literature methods, has been developed.
Conventional immunoassays rely on antibodies that provide high affinity, specificity, and selectivity against a target analyte.
Selection methods are used to identify Affimers that recognise α-helix mimicking